Literature DB >> 33580980

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.

Sangeetha Venugopal1, Abhishek Maiti1, Courtney D DiNardo1, Sanam Loghavi2, Naval G Daver1, Tapan M Kadia1, Caitlin R Rausch3, Yesid Alvarado1, Maro Ohanian1, Koji Sasaki1, Nicholas J Short1, Koichi Takahashi1, Musa Yilmaz1, Farhad Ravandi1, Hagop M Kantarjian1, Marina Y Konopleva1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33580980      PMCID： PMC8237705          DOI： 10.1002/ajh.26122

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


× No keyword cloud information.
  5 in total

1.  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

Authors:  Gail J Roboz; Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Alice S Mims; Gabrielle T Prince; Jessica K Altman; Martha L Arellano; Will Donnellan; Harry P Erba; Gabriel N Mannis; Daniel A Pollyea; Anthony S Stein; Geoffrey L Uy; Justin M Watts; Amir T Fathi; Hagop M Kantarjian; Martin S Tallman; Sung Choe; David Dai; Bin Fan; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Denice Hickman; Hua Liu; Samuel V Agresta; Bin Wu; Eyal C Attar; Richard M Stone
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

2.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Authors:  C D DiNardo; I S Tiong; A Quaglieri; S MacRaild; S Loghavi; F C Brown; R Thijssen; G Pomilio; A Ivey; J M Salmon; C Glytsou; S A Fleming; Q Zhang; H Ma; K P Patel; S M Kornblau; Z Xu; C C Chua; Xufeng Chen; P Blombery; C Flensburg; N Cummings; I Aifantis; H Kantarjian; D C S Huang; A W Roberts; I J Majewski; M Konopleva; A H Wei
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

3.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Authors:  Courtney D DiNardo; Abhishek Maiti; Caitlin R Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C Issa; Guillermo Montalban-Bravo; Nicholas J Short; Musa Yilmaz; Prithviraj Bose; Elias J Jabbour; Koichi Takahashi; Jan A Burger; Guillermo Garcia-Manero; Nitin Jain; Steven M Kornblau; Philip A Thompson; Zeev Estrov; Lucia Masarova; Koji Sasaki; Srdan Verstovsek; Alessandra Ferrajoli; William G Weirda; Sa A Wang; Sergej Konoplev; Zhining Chen; Sherry A Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S Welch; Hagop M Kantarjian; Marina Y Konopleva
Journal:  Lancet Haematol       Date:  2020-09-05       Impact factor: 18.959

4.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Brian A Jonas; Vinod Pullarkat; Michael J Thirman; Jacqueline S Garcia; Andrew H Wei; Marina Konopleva; Hartmut Döhner; Anthony Letai; Pierre Fenaux; Elizabeth Koller; Violaine Havelange; Brian Leber; Jordi Esteve; Jianxiang Wang; Vlatko Pejsa; Roman Hájek; Kimmo Porkka; Árpád Illés; David Lavie; Roberto M Lemoli; Kazuhito Yamamoto; Sung-Soo Yoon; Jun-Ho Jang; Su-Peng Yeh; Mehmet Turgut; Wan-Jen Hong; Ying Zhou; Jalaja Potluri; Keith W Pratz
Journal:  N Engl J Med       Date:  2020-08-13       Impact factor: 91.245

5.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476
  5 in total
  5 in total

Review 1.  Resistance to targeted therapies: delving into FLT3 and IDH.

Authors:  Sai Prasad Desikan; Naval Daver; Courtney DiNardo; Tapan Kadia; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2022-06-09       Impact factor: 9.812

2.  Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.

Authors:  Evan M Cherry; Diana Abbott; Maria Amaya; Christine McMahon; Marc Schwartz; Julie Rosser; Audrey Sato; Jeffrey Schowinsky; Anagha Inguva; Mohd Minhajuddin; Shanshan Pei; Brett Stevens; Amanda Winters; Craig T Jordan; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2021-12-28

3.  How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

Authors:  Abhishek Maiti; Marina Y Konopleva
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

4.  Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.

Authors:  Sangeetha Venugopal; Koichi Takahashi; Naval Daver; Abhishek Maiti; Gautam Borthakur; Sanam Loghavi; Nicholas J Short; Maro Ohanian; Lucia Masarova; Ghayas Issa; Xuemei Wang; Bueso-Ramos Carlos; Musa Yilmaz; Tapan Kadia; Michael Andreeff; Farhad Ravandi; Marina Konopleva; Hagop M Kantarjian; Courtney D DiNardo
Journal:  Blood Cancer J       Date:  2022-01-25       Impact factor: 9.812

Review 5.  Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.

Authors:  Mila S Griffioen; David C de Leeuw; Jeroen J W M Janssen; Linda Smit
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.